Cargando…

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study

Chromosomal abnormalities are established prognostic markers in adult ALL. We assessed the prognostic impact of established chromosomal abnormalities and key copy number alterations (CNA) among 652 patients with B-cell precursor ALL treated on a modern MRD driven protocol. Patients with KMT2A-AFF1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moorman, Anthony V., Barretta, Emilio, Butler, Ellie R., Ward, Eleanor J., Twentyman, Katie, Kirkwood, Amy A., Enshaei, Amir, Schwab, Claire, Creasey, Tom, Leongamornlert, Daniel, Papaemmanuil, Elli, Patrick, Pip, Clifton-Hadley, Laura, Patel, Bela, Menne, Tobias, McMillan, Andrew K., Harrison, Christine J., Rowntree, Clare J., Marks, David I., Fielding, Adele K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885405/ https://www.ncbi.nlm.nih.gov/pubmed/34657128 http://dx.doi.org/10.1038/s41375-021-01448-2

Ejemplares similares

Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials
por: Creasey, Thomas, et al.
Publicado: (2021)

In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial
por: Marks, David I, et al.
Publicado: (2022)

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
por: Patel, B, et al.
Publicado: (2017)

Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials
por: Enshaei, Amir, et al.
Publicado: (2021)

Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
por: Marks, David I, et al.
Publicado: (2022)

Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial
por: Schwab, Claire, et al.
Publicado: (2022)

Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia
por: Leongamornlert, Daniel, et al.
Publicado: (2023)

Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol‐E. coli L‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials
por: Sidhu, Jasmeet, et al.
Publicado: (2022)

Concordance of copy number abnormality detection using SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia
por: Bashton, Matthew, et al.
Publicado: (2020)

Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial
por: Jenkinson, S, et al.
Publicado: (2016)

Single nucleotide polymorphism array‐based signature of low hypodiploidy in acute lymphoblastic leukemia
por: Creasey, Thomas, et al.
Publicado: (2021)

The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI
por: Halsey, Christina, et al.
Publicado: (2011)

Characterisation of the genomic landscape of CRLF2‐rearranged acute lymphoblastic leukemia
por: Russell, Lisa J., et al.
Publicado: (2017)

Single cell analysis of clonal architecture in acute myeloid leukaemia
por: Potter, Nicola, et al.
Publicado: (2018)

Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol
por: Aslam, Sara, et al.
Publicado: (2021)

Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia
por: Li, Yilong, et al.
Publicado: (2014)

Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia
por: Sinclair, Paul B., et al.
Publicado: (2023)

HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial
por: Taylor, G M, et al.
Publicado: (2012)

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
por: Anderson, Richard A, et al.
Publicado: (2018)

Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups
por: Moorman, A V, et al.
Publicado: (2002)

Subclonal variant calling with multiple samples and prior knowledge
por: Gerstung, Moritz, et al.
Publicado: (2014)

Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia
por: Moorman, A V, et al.
Publicado: (2002)

Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia
por: Ciardullo, Carmela, et al.
Publicado: (2021)

Leukæmia and Pseudo-Leukæmia
Publicado: (1877)

Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia
por: Ryan, Sarra L., et al.
Publicado: (2023)

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
por: O’Connor, David, et al.
Publicado: (2018)

Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
por: Michels, Naomi, et al.
Publicado: (2021)

Immunotherapy in leukaemia: Immunotherapy in leukaemia
por: Mu, Xingmei, et al.
Publicado: (2023)

The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis
por: Hu, Xingdi, et al.
Publicado: (2019)

Acute Monocytic Leukæmia
por: Biggart, J. Henry
Publicado: (1945)

Therapy of Acute Leukaemias
por: Scarffe, J. H.
Publicado: (1980)

The Early Stages of Leukæmia
por: Caird, J. Colin
Publicado: (1940)

Acute Myelocytic Leukæmia
por: Elder, William, et al.
Publicado: (1904)

Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL
por: Fielding, Adele K., et al.
Publicado: (2020)

Leukaemia
por: Haworth, C.
Publicado: (1982)

Leukæmia
por: Kaupp, B. F.
Publicado: (1899)

Leukaemia
por: Vandeveer, George G.
Publicado: (1891)

Prediction of acute myeloid leukaemia risk in healthy individuals
por: Abelson, Sagi, et al.
Publicado: (2018)

Isoferritins in acute leukaemia.
por: Cragg, S. J., et al.
Publicado: (1977)

Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia
por: Pal, D, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n4l4eihsrbbq00lfrq5pn91bvn